Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22554317.
- Also identified by DOI 10.1021/nl301206p.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
Medical subject headings
- Cell Proliferation
- Extracellular Matrix
- Mammary Neoplasms, Experimental
- Nanocapsules
- Protein-Lysine 6-Oxidase